Aroa Biosurgery

Endoform restorative bioscaffolds can be used in the management of acute and chronic wounds.

Myriad Morcells Fine is a powdered bioscaffold utilizing the AROA ECM platform technology.

Interim results from the MASTRR Registry show low infection rates and no adverse events.

AROA and Mölnlycke Healthcare US will co-promote Endoform in the United States.

Keep updated with news and announcements.

Aroa Biosurgery develops, manufactures, and distributes medical and surgical products for soft-tissue repair and wound management.

Aroa Biosurgery is committed to offering products for soft tissue repair and managing wounds with AROA ECM platform technology.

HIPAA-Notice-of-Privacy-Practices-December-2022Download

Aroa Biosurgery Limited outlines its privacy policy, describing how it uses user information.

Aroa Biosurgery Limited (Aroa) licenses to the Licensee the right to use certain images, text, diagrams, animations and other material (Educational Material), on the following terms and conditions.

The page outlines terms and conditions for product evaluations.

The US Centers for Medicare & Medicaid Services (CMS) maintains the **$127.14 per square centimeter** reimbursement rate for **AROA ECM™ sheet products** in outpatient settings through 2027. This rate applies to wound treatments covered under existing CMS policies. The decision ensures continuity for providers using AROA’s extracellular matrix-based solutions.

Nov 2026Aroa BiosurgeryNews article

AROA appoints Mark Dunwoodie as Chief Financial Officer and Joint Company Secretary. He will begin his role on 16 November 2026, overseeing financial strategy and corporate governance.

Nov 2026Aroa BiosurgeryNews article

Mölnlycke Healthcare US partners exclusively with AROA to co-promote **Endoform™**, a medical product, in the United States starting October 16, 2026. The agreement marks a strategic collaboration to expand market reach and distribution for the product. No additional details on the product’s application or financial terms are disclosed.

Oct 2026Aroa BiosurgeryNews article

Aroa reports that a randomized controlled trial demonstrates Symphony™ accelerates healing in patients with diabetic foot ulcers. The study, published in the *International Wound Journal*, evaluates Symphony’s efficacy in a prospective, multicenter clinical setting. Results highlight its potential as a therapeutic intervention for chronic wound care.

Oct 2026Aroa BiosurgeryNews article